論文 - 詳細
| RRC ID | 65070 |
|---|---|
| 著者 | Shiiba M, Yamagami H, Yamamoto A, Minakawa Y, Okamoto A, Kasamatsu A, Sakamoto Y, Uzawa K, Takiguchi Y, Tanzawa H. |
| タイトル | Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity. |
| ジャーナル | Oncol Rep |
| Abstract |
Resistance to anticancer medications often leads to poor outcomes. The present study explored an effective approach for enhancing chemotherapy targeted against human cancer cells. Real-time quantitative real-time polymerase chain reaction (qRT-PCR) analysis revealed overexpression of members of aldo-keto reductase (AKR) 1C family, AKR1C1, AKR1C2, AKR1C3, and AKR1C4, in cisplatin, cis-diamminedichloroplatinum (II) (CDDP)-resistant human cancer cell lines, HeLa (cervical cancer cells) and Sa3 (oral squamous cell carcinoma cells). The genes were downregulated using small-interfering RNA (siRNA) transfection, and the sensitivity to CDDP or 5-fluorouracil (5-FU) was investigated. When the genes were knocked down, sensitivity to CDDP and 5-FU was restored. Furthermore, we found that administration of mefenamic acid, a widely used non-steroidal anti-inflammatory drug (NSAID) and a known inhibitor of AKR1Cs, enhanced sensitivity to CDDP and 5-FU. The present study suggests that AKR1C family is closely associated with drug resistance to CDDP and 5-FU, and mefenamic acid enhances their sensitivity through its inhibitory activity in drug-resistant human cancer cells. Thus, the use of mefenamic acid to control biological function of AKR1C may lead to effective clinical outcomes by overcoming anticancer drug resistance. |
| 巻・号 | 37(4) |
| ページ | 2025-2032 |
| 公開日 | 2017-4-1 |
| DOI | 10.3892/or.2017.5480 |
| PMID | 28259989 |
| MeSH | 20-Hydroxysteroid Dehydrogenases / antagonists & inhibitors 20-Hydroxysteroid Dehydrogenases / biosynthesis* 20-Hydroxysteroid Dehydrogenases / genetics 3-Hydroxysteroid Dehydrogenases / antagonists & inhibitors 3-Hydroxysteroid Dehydrogenases / biosynthesis* 3-Hydroxysteroid Dehydrogenases / genetics Aldo-Keto Reductase Family 1 Member C3 Cisplatin / administration & dosage Drug Resistance, Neoplasm / drug effects Fluorouracil / administration & dosage Gene Expression Regulation, Neoplastic / drug effects HeLa Cells Humans Hydroxyprostaglandin Dehydrogenases / antagonists & inhibitors Hydroxyprostaglandin Dehydrogenases / biosynthesis* Hydroxyprostaglandin Dehydrogenases / genetics Hydroxysteroid Dehydrogenases / antagonists & inhibitors Hydroxysteroid Dehydrogenases / biosynthesis* Hydroxysteroid Dehydrogenases / genetics Mefenamic Acid / administration & dosage* Neoplasms / drug therapy* Neoplasms / genetics Neoplasms / pathology Oxidoreductases |
| IF | 3.417 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | Sa3(RCB0980) |